0001104659-20-089141.txt : 20200731 0001104659-20-089141.hdr.sgml : 20200731 20200731165520 ACCESSION NUMBER: 0001104659-20-089141 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200729 FILED AS OF DATE: 20200731 DATE AS OF CHANGE: 20200731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rowland Charles A Jr CENTRAL INDEX KEY: 0001383292 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 201066672 MAIL ADDRESS: STREET 1: 3338 LANCASHIRE RD CITY: FURLONG STATE: PA ZIP: 18925 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2020-07-29 0 0001641640 Nabriva Therapeutics plc NBRV 0001383292 Rowland Charles A Jr 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 1 0 0 0 Ordinary Shares 2020-07-29 4 A 0 17500 0 A 70500 D Stock Options 0.79 2020-07-29 4 A 0 35000 0 A 2030-07-28 Ordinary Shares 35000 35000 D The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units. The option was granted on July 29, 2020. One hundred percent (100%) of the option will vest on July 31, 2021, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc. /s/ Robert Crotty, by power of attorney 2020-07-31